One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients

American Journal of Ophthalmology

Volumn 154, Issue 1, 2012, Pages 117-124.e1

  Hikichi, Taiichi ^a   Higuchi, Makoto ^a   Matsushita, Takuro ^a   Kosaka, Shoko ^a   Matsushita, Reiko ^a   Takami, Kimitaka ^a   Ohtsuka, Hideo ^a   Ariga, Hiroko ^a  

^a Ohtsuka Eye Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; EYE FUNDUS; FEMALE; FOLLOW UP; HUMAN; INDOCYANINE GREEN ANGIOGRAPHY; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; POLYPOIDAL CHOROIDAL VASCULOPATHY; PRIORITY JOURNAL; RETINA FOVEA; RETINA HEMORRHAGE; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

EID: 84862765983     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2011.12.019     Document Type: Article

References (41)

1. Chan WM, Lam DS, Lai TYY, et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy. one-year results of a prospective case series. Ophthalmology 2004;111(8):1576-1584. (Pubitemid 39030815)
2. Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008;92(12):1642-1647.
3. Spaide RF, Donsoff I, Lam DL, et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 2002;22(5):529-535. (Pubitemid 35176066)
4. Quaranta M, Maget-Faysse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmol 2002;134(2):277-280. (Pubitemid 34831840)
5. Lee SC, Seong YS, Kim SS, et al. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica 2004;218(3):193-201. (Pubitemid 38596586)
6. Silva RM, Figueria J, Cachulo ML, et al. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefes Arch Clin Exp Ophthalmol 2005;243(10):973-979.
7. Otani A, Sasahara M, Yodoi Y, et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007;144(1):7-14.
8. Eandi CM, Ober MD, Freund KB, et al. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina 2007;27(7):825-831. (Pubitemid 47479375)
9. Akaza E, Mori R, Yuzawa M. Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina 2008;28(5):717-722. (Pubitemid 351655124)
10. Kurashige Y, Otani A, Sasahara M, et al. Two-year results of photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2008;146(4):513-519.
11. Gomi F, Ohji M, Sayanagi K, et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008;115(1):141-146. (Pubitemid 350309415)
12. Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H. Twoyear visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009;29(7):960-965.
13. Wakabayashi T, Gomi F, Sawa M, et al. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 2008;92(7):936-940. (Pubitemid 351969674)
14. Hirami Y, Tsujikawa A, Otani A, et al. Hemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2007;27(3):335-341. (Pubitemid 46398898)
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1432- 1444. (Pubitemid 44511558)
16. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-1431. (Pubitemid 44511557)
17. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: an interim 6-month report. Br J Ophthalmol 2010;94(3):297-301.
18. Hikichi T, Ohtsuka H, Higuchi M, et al. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months. Am J Ophthalmol 2010;150(5):674-682.
19. Uyama M, Matsubara T, Fukushima, et al. Idiopathic polypoidal choroidal vasculopathy in Japanese patients. Arch Ophthalmol 1999;117(8):1035-1042. (Pubitemid 29372936)
20. Uyama M, Wada M, Nagai Y, et al. Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133(5):639-648. (Pubitemid 34462012)
21. Sho K, Takahashi K, Yamada H, et al. Polypoidal choroidal vasculopathy. incidence, demographic features, and clinical characteristics. Arch Ophthalmol 2003;121(10):1392-1396. (Pubitemid 37243739)
22. Rouvas AA, Papakostas TD, Ntouraki A, et al. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina 2011;31(3):464-474.
23. Japanese Study Group of Polypoidal Choroidal Vasculopathy. Criteria for diagnosis of polypoidal choroidal vasculopathy [in Japanese]. Nippon Ganka Gakkai Zasshi 2005;109(7):417- 427.
24. Costa RA, Calucci D, Skaf M, et al. Optical coherence tomography 3: automatic delineation of the outer neural retinal boundary and its influence on retinal thickness measurements. Invest Ophthalmol Vis Sci 2004;45(7):2399-2406. (Pubitemid 38902615)
25. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
26. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148(1):43-58.
27. Tano Y, Ohji M; EXTEND-I study group. EXTEND-1: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 2010;88(3):309-316.
28. Ahlers C, Golbaz I, Stock G, et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology 2008;115(8):e39-e46.
29. Ahlers C, Golbaz I, Einwallner E, et al. Identification of optical density ratios in subretinal fluid as a clinically relevant biomarker in exudative macular disease. Invest Ophthalmol Vis Sci 2009;50(7):3417-3424.
30. Golbaz I, Ahlers C, Stock G, et al. Quantification of the therapeutic response of intraretinal, subretinal and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011;52(3):1599-1605.
31. Lee MW, Yeo I, Wong D, Ang CL. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy. Eye (Lond) 2009;23(6):1417-1422.
32. Hikichi T, Ohtsuka H, Higuchi M, et al. Factors predictive of visual acuity outcomes 1 year after photodynamic therapy Japanese patients with polypoidal choroidal vasculopathy. Retina 2011;31(5):857- 865.
33. Stangos AN, Gandhi JS, Nair-Sahni J, et al. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010;150(5):666-673.
34. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2011;95(11):1555-1559.
35. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113(7):1040-1050. (Pubitemid 38544126)
36. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003;111(9):1287-1295. (Pubitemid 36554699)
37. Lafaut BA, Aisenbrey S, van den Broecke C, et al. Polypoidal choroidal vasculopathy pattern in age-related macular degeneration. A clinicopathologic correlation. Retina 2000;20(6):650-654. (Pubitemid 32427983)
38. Okubo A, Sameshima M, Uemura A, et al. Clinicopathological correlation of polypoidal choroidal vasculopathy revealed by ultrastructural study. Br J Ophthalmol 2002;86(10): 1093-1098.
39. Nakashizuma H, Mitsumata M, Okisaka S, et al. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 2008;49(11):4729-4737.
40. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246(4935):1306-1309. (Pubitemid 20066716)
41. Barbazetto I, Saroj N, Shapiro H, Wong P, Freund B. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. Retina 2010;30(9):1376-1385.